BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 33504104)

  • 1. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    Torre BG; Albericio F
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Pharmaceutical Industry in 2021. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2022 Feb; 27(3):. PubMed ID: 35164339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pharmaceutical Industry in 2022: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pharmaceutical Industry in 2023: An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    G de la Torre B; Albericio F
    Molecules; 2019 Feb; 24(4):. PubMed ID: 30813407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Pharmaceutical Industry in 2016. An Analysis of FDA Drug Approvals from a Perspective of the Molecule Type.
    Torre BG; Albericio F
    Molecules; 2017 Feb; 22(3):. PubMed ID: 28264468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2021 FDA TIDES (Peptides and Oligonucleotides) Harvest.
    Al Shaer D; Al Musaimi O; Albericio F; de la Torre BG
    Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
    Darrow JJ; Avorn J; Kesselheim AS
    JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Approvals of Biologics in 2022.
    Martins AC; Albericio F; de la Torre BG
    Biomedicines; 2023 May; 11(5):. PubMed ID: 37239105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2023 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent drug approvals from the US FDA and EMEA: what the future holds.
    Pevarello P
    Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. US-FDA Approved Drugs in 2020 and 2021: A Review.
    Passi I; Salwan S; Kumar B
    Mini Rev Med Chem; 2023; 23(12):1273-1297. PubMed ID: 36503454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2022 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ophthalmic Drug Discovery in the United States over the past Two Decades.
    Gu D; Janetos TM
    Ophthalmic Epidemiol; 2021 Feb; 28(1):21-26. PubMed ID: 32597285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.